Test Details
Methodology
Enzyme-linked immunosorbent assay (ELISA)
Result Turnaround Time
5 - 7 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Test Includes
This test is a component of Interstitial Lung Disease Panel I, Interstitial Lung Disease Panel II, ILdx Complete, MyoMarker 3 Plus Profile, MyoMarker 3 Profile.
Use
The presence of these antibodies, when considered in conjunction with other laboratory and clinical findings, is an aid in the diagnosis of systemic lupus erythematosus (SLE), Sjögren’s Syndrome (SS), systemic sclerosis (SSC), polymyositis (PM) and dermatomyositis (DM). SS-A/Ro antigen are found in 40% to 60% of patients with Sjögren’s Syndrome and in 25% to 35% of patients with SLE.
At one time it was thought that two different proteins, SS-A 52 and SS-A 60, were needed to account for SS-A antigenic reactivity. Now it is known that SS-A 52 and SS-A 60 proteins are not linked in the same particle. In addition, anti-SS-A 52 autoantibodies are distinct from, and have a different clinical utility than, anti-SS-A 60 antibodies.
Just like anti-SS-A 60, anti-SS-A 52 is commonly found in patients with SLE and Sjgren's Syndrome, and occasionally in other autoimmune disorders. However, anti-SS-A 52 autoantibodies are also found in patients with systemic sclerosis, polymyositis and dermatomyositis. Anti-SSA 52 are linked with antibodies to tRNA synthetases like Jo-1, PL-7, PL-12, EJ and OJ, which are often found in patients with interstitial lung involvement.
Studies show that 10% to 45% of myositis is positive with SSA52 antibody. An RDL study revealed 38% of myositis patients (18/47) were positive for SS-A 52 antibody. RDL offers SS-A 52 antibody test as part of the myositis panel.
The presence of these antibodies, when considered in conjunction with other laboratory and clinical findings, is an aid in the diagnosis of systemic lupus erythematosus (SLE), Sjögren’s Syndrome (SS), systemic sclerosis (SSC), polymyositis (PM) and dermatomyositis (DM). SS-A/Ro antigen are found in 40 |
The presence of these antibodies, when considered in conjunction with other laboratory and clinical findings, is an aid in the diagnosis of systemic lupus erythematosus (SLE), Sjögren’s Syndrome (SS), systemic sclerosis (SSC), polymyositis (PM) and dermatomyositis (DM). SS-A/Ro antigen are found in 40% to 60% of patients with Sjögren’s Syndrome and in 25% to 35% of patients with SLE. At one time it was thought that two different proteins, SS-A 52 and SS-A 60, were needed to account for SS-A antigenic reactivity. Now it is known that SS-A 52 and SS-A 60 proteins are not linked in the same particle. In addition, anti-SS-A 52 autoantibodies are distinct from, and have a different clinical utility than, anti-SS-A 60 antibodies. Just like anti-SS-A 60, anti-SS-A 52 is commonly found in patients with SLE and Sjgren's Syndrome, and occasionally in other autoimmune disorders. However, anti-SS-A 52 autoantibodies are also found in patients with systemic sclerosis, polymyositis and dermatomyositis. Anti-SSA 52 are linked with antibodies to tRNA synthetases like Jo-1, PL-7, PL-12, EJ and OJ, which are often found in patients with interstitial lung involvement. Studies show that 10% to 45% of myositis is positive with SSA52 antibody. An RDL study revealed 38% of myositis patients (18/47) were positive for SS-A 52 antibody. RDL offers SS-A 52 antibody test as part of the myositis panel. |
Limitations
This anti-Ro52 test is performed by enzyme immunoassay, and its numeric results cannot be used additively with measurements of anti-Ro60 by chemiluminescent immunoassay. The sum of two measurements do not equate to total Ro antibodies. Results should be interpreted in the context of other laboratory and clinical findings. Negative results do not exclude the possibility of autoimmune disease.
This anti-Ro52 test is performed by enzyme immunoassay, and its numeric results cannot be used additively with measurements of anti-Ro60 by chemiluminescent immunoassay. The sum of two measurements do not equate to total Ro antibodies. Results should be interpreted in the context of other laboratory and clinical findings. Negative results do not exclude the possibility of autoimmune disease. |
Custom Additional Information
This test is one measurement of anti-Ro52 antibodies by enzyme immunoassay. Anti-Ro occur in 60% to 90% of patients with Sjögren’s Syndrome (SS), in 30% to 50% of patients with systemic lupus erythematosus (SLE) and less frequently in other autoimmune diseases.
Historically, autoantibodies to both parts of the Ro (SS-A) antigen, Ro52kilodaltons and Ro60kilodaltons, have been used to comprise total anti-Ro. Now, it is known that Ro52 and Ro60 proteins are not linked in the same particle. In addition, anti-Ro52 and anti-Ro60 are distinct from each other and have different clinical associations.
Ro52, also known as tripartite motif 21 (TRIM21), is implicated in ubiquitination, pro-inflammatory states and apoptosis mechanisms. Anti-Ro52 occur in SS, SLE, neonatal lupus erythematosus, subacute cutaneous lupus erythematosus, autoimmune hepatitis, systemic sclerosis (SSc) and idiopathic inflammatory myositis (IIM).
Anti-Ro52 antibodies are implicated as a risk factor for interstitial lung disease (ILD) in patients with autoimmune myositis, Sjogren’s, systemic sclerosis (SSc) and mixed connective tissue disease (MCTD). Dual positivity of anti-Ro52 with anti-Jo1 or antibodies to other tRNA synthetases like PL-7, PL-12, EJ and OJ confers a much greater risk of interstitial lung involvement.
This test is one measurement of anti-Ro52 antibodies by enzyme immunoassay. Anti-Ro occur in 60% to 90% of patients with Sjögren’s Syndrome (SS), in 30% to 50% of patients with systemic lupus erythematosus (SLE) and less frequently in other autoimmune diseases. Historically, autoantibodies to both parts of the Ro (SS-A) antigen, Ro52kilodaltons and Ro60kilodaltons, have been used to comprise total anti-Ro. Now, it is known that Ro52 and Ro60 proteins are not linked in the same particle. In addition, anti-Ro52 and anti-Ro60 are distinct from each other and have different clinical associations. Ro52, also known as tripartite motif 21 (TRIM21), is implicated in ubiquitination, pro-inflammatory states and apoptosis mechanisms. Anti-Ro52 occur in SS, SLE, neonatal lupus erythematosus, subacute cutaneous lupus erythematosus, autoimmune hepatitis, systemic sclerosis (SSc) and idiopathic inflammatory myositis (IIM). Anti-Ro52 antibodies are implicated as a risk factor for interstitial lung disease (ILD) in patients with autoimmune myositis, Sjogren’s, systemic sclerosis (SSc) and mixed connective tissue disease (MCTD). Dual positivity of anti-Ro52 with anti-Jo1 or antibodies to other tRNA synthetases like PL-7, PL-12, EJ and OJ confers a much greater risk of interstitial lung involvement. |
Specimen Requirements
Specimen
Serum
Volume
2 mL
Minimum Volume
0.5 mL (Note: This volume does not allow for repeat testing.)
Container
Red-top tube or gel-barrier tube
Collection Instructions
Separate serum from cells within one hour of collection. Transfer to a plastic transport tube before shipping. To avoid delays in turnaround time when requesting multiple tests on frozen samples, please submit separate frozen specimens for each test requested.
Stability Requirements
| Temperature | Period |
|---|---|
| Room temperature | 7 days |
| Refrigerated | 14 days |
| Frozen | 60 days |
| Freeze/thaw cycles | Stable x1 |
Storage Instructions
Refrigerate or freeze.
Causes for Rejection
Grossly hemolyzed; bacterial contamination; lipemic specimen; icteric specimen; non-serum specimen types
References
Chan EKL. Anti-Ro52 Autoantibody Is Common in Systemic Autoimmune Rheumatic Diseases and Correlating with Worse Outcome when Associated with interstitial lung disease in Systemic Sclerosis and Autoimmune Myositis. Clin Rev Allergy Immunol. 2022 Oct;63(2):178-193. PubMed 35040083
Weng CT, Huang TH, Wu, CH, Sun YT. Association of anti-Ro-52 antibodies with occurrence of interstitial lung disease in patients with idiopathic inflammatory myopathy. Arthritis Res Ther. 24 Aug 22;26(1):152. PubMed 39175076
Chan EKL. Anti-Ro52 Autoantibody Is Common in Systemic Autoimmune Rheumatic Diseases and Correlating with Worse Outcome when Associated with interstitial lung disease in Systemic Sclerosis and Autoimmune Myositis. Clin Rev Allergy Immunol. 2022 Oct;63(2):178-193. PubMed 35040083 Weng CT, Huang TH, Wu, CH, Sun YT. Association of anti-Ro-52 antibodies with occurrence of interstitial lung disease in patients with idiopathic inflammatory myopathy. Arthritis Res Ther. 24 Aug 22;26(1):152. PubMed 39175076 |
LOINC® Map
| Order Code | Order Code Name | Order Loinc | Result Code | Result Code Name | UofM | Result LOINC |
|---|---|---|---|---|---|---|
| 520015 | Anti-Ro52 (SS-A 52kD) (RDL) | 56549-9 | 520039 | Anti-Ro52 (SS-A 52kD) (RDL) | Units | 70257-1 |
| Order Code | 520015 | |||||
| Order Code Name | Anti-Ro52 (SS-A 52kD) (RDL) | |||||
| Order Loinc | 56549-9 | |||||
| Result Code | 520039 | |||||
| Result Code Name | Anti-Ro52 (SS-A 52kD) (RDL) | |||||
| UofM | Units | |||||
| Result LOINC | 70257-1 |